Table 2.

Dynamic change of risk prediction model scores at different on-treatment timepoints

Models		Before AVT (n=660)	On-treatment timepoints
			Year 2.5 (n=660)	Year 3 (n=640)	Year 3.5 (n=622)	Year 4 (n=603)	Year 4.5 (n=589)	Year 5 (n=562)
Untreated models without the cirrhosis variable
	REACH-B	10.14±2.48	5.93±2.14	5.87±2.07	6.13±2.12	6.07±2.05	5.98±2.03	5.97±2.00
	NGM1	8.32±2.48	6.66±2.51	6.69±2.39	6.77±2.45	6.94±2.47	6.60±2.37	6.73±2.34
	NGM2	11.20±2.67	7.87±3.41	7.81±3.17	7.95±3.31	8.13±3.34	7.43±3.08	7.51±2.97
Untreated models with the cirrhosis variable
	GAG-HCC	92.92±22.05	75.88±22.43	76.49±21.69	76.55±21.57	76.88±21.82	76.20±21.13	74.73±20.98
Treated or mixed models without the cirrhosis variable
	mREACH-BI	8.03±2.18	6.55±2.34	6.38±2.23	6.60±2.26	6.60±2.25	6.47±2.21	6.49±2.19
	mREACH-BII	9.48±2.64	7.23±2.82	6.98±2.68	7.17±2.71	7.20±2.69	7.02±2.63	7.07±2.60
	LSM-HCC	16.36±7.41	9.02±8.13	8.41±7.98	8.45±7.98	8.56±7.76	8.57±7.89	8.85±7.84
	SAGE-B	7.04±3.47	5.30±3.31	5.20±3.15	5.23±3.15	5.37±3.08	5.44±3.11	5.56±3.00
	mPAGE-B	10.33±3.24	9.98±3.18	10.08±3.07	10.00±2.99	10.22±3.05	10.15±2.98	10.36±2.93
	PAGE-B	14.49±4.57	14.00±4.88	14.03±4.78	13.79±4.71	14.09±4.77	13.90±4.72	14.22±4.69
	aMAP	60.36±7.56	58.74±7.52	58.58±7.44	58.47±7.44	58.51±7.43	58.43±7.37	58.79±7.30
Treated or mixed models with the cirrhosis variable
	AASL-HCC	13.25±6.69	11.37±6.51	11.60±6.43	11.46±6.37	11.67±6.52	11.41±6.29	10.93±6.19
	CAMD	10.10±5.14	9.30±5.21	9.57±5.11	9.49±5.07	9.70 ±5.22	9.60±5.02	9.40±4.94
	REAL-B	5.11±2.13	4.57±2.07	4.64±2.04	4.57±1.97	4.69±2.05	4.59±1.96	4.54±1.91
	CU-HCC	16.12±11.15	8.68±8.51	8.74±8.54	8.50±8.18	8.52±8.49	8.30±8.29	7.36±8.18
	RWS-HCC	4.57±2.07	3.26±1.86	3.28±1.80	3.22±1.74	3.17±1.74	3.14±1.73	2.91±1.74
	CAGE-B	7.32±3.91	6.66±3.56	6.69±3.46	6.70±3.44	6.86±3.41	6.90±3.43	7.03±3.34

Model scores were expressed as mean±standard deviation.

AVT, antiviral treatment; HCC, hepatocellular carcinoma; LSM, liver stiffness measurement.